Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Are LGBTQ+ Allyship Symbols Associated With Patient Trust in the Orthopaedic Surgeon? A Dual Cohort Survey.

Clinical orthopaedics and related research·2026
Same author

Cyclophilin D, Regulator of Mitochondrial Permeability Transition and Bioenergetics, Promotes Adipogenic Differentiation of Mesenchymal Stem Cells.

Cells·2026
Same author

Taurine transporter SLC6A6 expression promotes mesenchymal stromal cell function.

Cell death & disease·2026
Same author

2025 ICM: Use of Newer Antibiotics and Fluoroquinolone-Resistance.

The Journal of arthroplasty·2025
Same author

Another International Consensus Meeting Concludes: We Are Here for the Patients.

The Journal of arthroplasty·2025
Same author

The Overexpression of BMP Type I Receptor ALK3 Has a Protective Effect in Degenerative Disc Disease in a Mouse Model.

Spine·2025

Related Experiment Video

Updated: May 27, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Targeting radioresistant osteosarcoma cells with parthenolide.

Daniel Zuch1, An-Hoa Giang, Yuriy Shapovalov

  • 1Center for Musculoskeletal Research, University of Rochester School of Medicine & Dentistry, 575 Elmwood Ave., Rochester, New York 14642, USA.

Journal of Cellular Biochemistry
|November 24, 2011
PubMed
Summary

Parthenolide re-sensitizes osteosarcoma cancer stem cells to radiation. This combination therapy synergistically reduces cell death, potentially decreasing cancer relapse and metastasis.

More Related Videos

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: May 27, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Area of Science:

  • Oncology
  • Cancer Biology
  • Radiotherapy Research

Background:

  • Osteosarcoma is a primary bone cancer predominantly affecting adolescents.
  • Osteosarcoma exhibits significant radioresistance, leading to high rates of relapse and metastasis.
  • Cancer stem cells (CSCs) within osteosarcoma contribute to treatment resistance and tumor regeneration.

Purpose of the Study:

  • To investigate if parthenolide can re-sensitize osteosarcoma cells, including CSCs, to radiotherapy.
  • To evaluate the synergistic effects of parthenolide and ionizing radiation on osteosarcoma cell death.
  • To determine the role of oxidative stress in parthenolide-mediated radiosensitization.

Main Methods:

  • In vitro treatment of LM7 osteosarcoma cells with parthenolide and ionizing radiation.
  • Assessment of cell viability in both the general cell population and CSC subpopulation.
  • Analysis of parthenolide's mechanism of action, focusing on oxidative stress induction.

Main Results:

  • Parthenolide and ionizing radiation demonstrated synergistic induction of cell death in osteosarcoma cells.
  • The combination treatment significantly reduced the viability of both bulk osteosarcoma cells and CSCs.
  • Parthenolide's radiosensitizing effect was dependent on its ability to induce oxidative stress.

Conclusions:

  • Parthenolide may serve as a valuable adjunct to current multimodal therapy for osteosarcoma.
  • Combining parthenolide with radiation could enhance treatment efficacy and reduce the incidence of relapse and metastasis.
  • Targeting CSCs with parthenolide offers a promising strategy to overcome radioresistance in osteosarcoma.